Targeting the host CCL5, via nanoparticle-delivered siRNA, in combination with Maraviroc (an FDA-approved CCR5 inhibitor) resulted in reductions of circulating immunosuppressive monocyte and neutrophils in both 4T1 and PyMT tumor-bearing mice, enhancing robust antitumor responses [171]. Here, CCR5 is linked to neoplasm.